Oncology advances through the lens of women in STEM
Dr Pooja Hingorani opens up about her journey in oncology research, the obstacles she’s overcome as a woman in STEM, and her mission to transform cancer care.
List view / Grid view
Dr Pooja Hingorani opens up about her journey in oncology research, the obstacles she’s overcome as a woman in STEM, and her mission to transform cancer care.
The human body has an incredible ability to repair itself, both from acute trauma and chronic damage that accumulates as we age. Here, Cameron Lee, Principal Scientist at Tune Therapeutics, reveals the potential of harnessing the body’s natural regenerative capabilities with epigenetic control of stem cells.
Anirban Datta, Head of Discovery Biology at Verseon International Corporation, details how recent breakthroughs are bringing once-distant possibilities, such as testing drugs more efficiently and restoring lost organ function through implantation, closer to reality.
The findings offer a promising drug target to prevent progression to colon cancer by targeting abnormal cells early on.
By studying organoids derived from adult stem cells, researchers made a discovery that could improve the development of personalised therapeutics.
Cincinnati Children’s have repaired damaged intestines in a rodent model, moving research efforts closer to clinical trials.
Understanding the signalling pathway controlling neural stem cell reactivation could offer a strategy for using existing drugs to treat neurodevelopmental disorders.
Organoids with SMA-pathology uncovered key findings about the disease, which could be utilised to develop new therapeutic options.
31 July 2024 | By bit.bio
Watch this webinar to discover the latest astrocyte research and its implications for CNS drug discovery.
The agreement between Cartherics, The University of Sydney and The University of Queensland will further stem cell-derived heart muscle therapy for heart failure.
Mini-colons, which closely resemble in vivo tissue, were used for several applications, including the characterisation of anticancer drug toxicity profiles.
In this episode, we discuss how new insights into stem cell biology are leading to novel therapeutics in regenerative medicine beyond cell therapy.
We had the privilege of interviewing Brian Culley, CEO of Lineage Cell Therapeutics. He discusses how Lineage’s pluripotent stem cell platform is extraordinarily advantageous, details two early-stage programmes addressing auditory and vision disorders and reveals how Lineage is choosing to target conditions that will make a real difference.
The world’s first generation of human BBB organoids from hPSCs accurately replicated features of cerebral cavernous malformation.
Culture conditions during embryoid body formation can be enhanced to gain glia-associated proteins and neural network activity.